4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Published online 2 September 2008
Haematologica, Vol 93, Issue 12, 1894-1898 doi:10.3324/haematol.13112
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chamuleau, M. E.D.
Right arrow Articles by Ossenkoppele, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chamuleau, M. E.D.
Right arrow Articles by Ossenkoppele, G. J.

Acute Myeloid Leukemia

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

Martine E.D. Chamuleau1, Arjan A. van de Loosdrecht1, Corine J. Hess1, Jeroen J.W.M. Janssen1, Adri Zevenbergen1, Ruud Delwel2, Peter J.M. Valk2, Bob Löwenberg2, Gert J. Ossenkoppele1

1 Department of Hematology, VU University Medical Centre, Amsterdam
2 Department of Hematology, Erasmus University Medical Centre, Rotterdam, the Netherlands

Correspondence: Martine E.D. Chamuleau, MD, Department of Hematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. E-mail:m.chamuleau{at}vumc.nl

Indoleamine 2,3-dioxygenase degrades the amino acid tryptophan which is essential for T cells. Tryptophan depletion causes T-cell cycle arrest and solid tumors that express high levels of indoleamine 2,3-dioxygenase can create immune suppression. Recently, blasts of patients with acute myeloid leukemia were shown to express indoleamine 2,3-dioxygenase. We determined INDO (encoding gene for indoleamine 2,3-dioxygenase) mRNA expression in leukemic blasts of 286 patients with acute myeloid leukemia by gene-expression profiling. Results were validated by quantitative polymerase chain reaction analysis in blasts of an independent cohort of 71 patients. High INDO expression was correlated to significantly shortened overall and relapse-free survival. Correlation of INDO expression to relevant known prognostic factors and survival identified high INDO expression as a strong negative independent predicting variable for overall and relapse-free survival. Inhibition of indoleamine 2,3-dioxygenase expressed by myeloid leukemic blasts may result in breaking immune tolerance and offers new therapeutic options for patients with acute myeloid leukemia.

Key words: indoleamine 2,3-dioxygenase, INDO, acute myeloid leukemia, immunesurveillance, immunetherapy.




This article has been cited by other articles:


Home page
 haematolHome page
ERRATA CORRIGE
Haematologica, August 1, 2009; 94(8): 1182 - 1182.
[Full Text] [PDF]

Home page
 BloodHome page
U. Keilholz, A. Letsch, A. Busse, A. M. Asemissen, S. Bauer, I. W. Blau, W.-K. Hofmann, L. Uharek, E. Thiel, and C. Scheibenbogen
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Blood, June 25, 2009; 113(26): 6541 - 6548.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood, March 12, 2009; 113(11): 2394 - 2401.
[Abstract] [Full Text] [PDF]